17-fold surge in five days: the frenzy around an AI fund and a generation's FOMO

A tradable ticket to private AI upside

A closed‑end fund with the ticker VCX listed on the New York Stock Exchange and promptly exploded. It has been reported that the price climbed as high as $575 within days of listing — roughly a 17‑fold move from its opening price — drawing reportedly more than 100,000 investors into a trade that many say was driven more by FOMO than fundamentals. The fund’s published net asset value (NAV) sits near $18.97, and early buyers face a 180‑day lockup if they purchased before February 20; so what most people bought was a liquid claim on private AI upside, not direct stock in the underlying companies.

A concentrated box of the rarest AI stakes

VCX is reportedly heavily concentrated in private AI assets: about 85% of the portfolio is private, only ~1% is public, and nearly half the fund’s weight is devoted to AI names. The largest reported allocations include Anthropic (~20.7%), Databricks (~17.7%) and OpenAI (~9.9%). But this is a closed‑end structure — you cannot convert your VCX shares into Anthropic or OpenAI stock — so daily price swings reflect sentiment and scarcity rather than the liquidity of the underlying unicorns. In short: the market was buying a tradable “box” of blockbuster private companies and then trading the box itself.

Why this matters: markets, money and geopolitics

The episode exposes a broader trend in today’s tech capital markets: companies stay private longer (“private for longer”), private valuations and revenues have ballooned for top AI firms, and liquid outlets for ordinary investors to access that upside are scarce. It has been reported that global investable private capital rose sharply in recent years — part of the reason IPOs are less common — and that dynamic feeds speculative demand for instruments like VCX. Against the backdrop of an intensifying US–China AI competition, export controls and sanctions also complicate direct access to leading AI assets for some investors, amplifying appetite for any tradable proxy. Democratization of venture capital? Or financial theater dressed as access? The VCX saga suggests both answers are true.